A Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin
This is a randomized, double-blind, placebo-controlled, fully decentralized (remote) clinical trial evaluating the effects of Broc Shot Capsules on skin appearance and comfort in adults with reactive, blemish-prone, or hormonally affected skin. Fifty participants aged 18-65 years will be randomly assigned in a 1:1 ratio to receive either Broc Shot Capsules (active) or matched placebo capsules for 8 weeks.
Participants will take 2 capsules once daily and complete self-reported questionnaires and standardized self-captured skin photographs at Baseline, Week 4, and Week 8 via a secure online study platform. Expert dermatologist grading of photographs will be conducted remotely at each timepoint. The study is designed to substantiate consumer product claims related to visible skin improvement and participant-reported skin comfort, and is not intended to evaluate treatment of any clinical dermatological disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gracia Walker
- Email: gracia@brocshot.com
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89101
- Citruslabs
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 to 65 years (inclusive) at the time of consent.
- Self-reported skin concerns matching at least one of the following descriptions: I have red, itchy skin patches
- I have dry, flaky/scaley skin patches
- my skin has blemishes such as pimples, discoloured papules (small, tender bumps that are pink/red/purple/or darker than your natural skin tone) or pustules (a distinct white or yellow pus-filled center surrounded by a red base).
- Generally healthy adults who are willing and able to follow the study protocol for the full 8-week duration, including taking 2 capsules of the study product once daily for 8 consecutive weeks without skipping days, answering questionnaires at Baseline, Week 4, and Week 8, and following the photograph submission protocol at Baseline, Week 4, and Week 8.
- Willing to avoid initiating any new topical or oral skincare products, prescription medications targeting skin, or other dietary supplements specifically marketed for skin benefit during the study period.
- Participants currently using such products who have been using them consistently for at least 3 months prior to enrollment and are willing to continue unchanged throughout the study are eligible.
- Willing to maintain their current diet, lifestyle, sleep pattern, sun exposure habits, and skincare routine for the duration of the trial.
- Resides within the United States.
- Access to a smartphone or computer with internet connection and the ability to use the Citruslabs digital study platform.
Exclusion Criteria:
- Known allergy, hypersensitivity, or intolerance to broccoli, horseradish, other cruciferous vegetables (Brassicaceae family), or any component of the study product or placebo capsule.
- Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
- Currently taking prescription anticoagulant medications (e.g., warfarin, apixaban, rivaroxaban) due to the potential for product ingredients to interact with anticoagulant activity.
- History of a severe or unstable medical condition that, in the opinion of the study team, would prevent safe participation or adherence to the protocol, including active cancer treatment.
- Currently using any oral, topical, or biologic prescription medication specifically indicated for a diagnosed dermatological condition, unless the regimen has been stable for at least 3 months and no changes are planned during the study period.
- Planned dermatological procedures during the study period (e.g., chemical peels, laser treatments, microneedling, injectable cosmetic procedures) that could confound skin appearance assessments.
- Currently enrolled in another clinical or consumer research study, or plans to enroll in any such study during the 8-week study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Comparator
|
Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids. |
|
Experimental: BrocShot Collagen
|
Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinician-Assessed Change in Overall Skin Appearance
Time Frame: Baseline to Week 8
|
Change from Baseline in overall skin appearance graded by a qualified dermatologist reviewing participant-submitted digital photographs using a binary Yes/No improvement scale assessing overall skin health, pigmentation, dryness, brightness, scarring, blemishes, redness, and flaking |
Baseline to Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant-Reported Change in Skin Appearance
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin appearance assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Clarity
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin clarity assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Calmness
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin calmness assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Visible Skin Concerns
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported visible skin concerns assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Texture
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin texture assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Luminosity
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin luminosity assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Age Appearance
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin age appearance assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Itching and Irritation
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported itching and irritation assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Comfort
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin comfort assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
|
Participant-Reported Change in Skin Confidence
Time Frame: Baseline, Week 4, and Week 8
|
Change from Baseline in self-reported skin confidence assessed via a participant-reported skin questionnaire |
Baseline, Week 4, and Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BROCS-84181
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.